'For
the quarter ending March 2024, standalone net sales (including other operating income) of Sanofi India has declined 0.56% to Rs 732.40 crore compared to quarter ended March 2023. Operating profit margin has declined from 31.22% to 29.89%, leading to 4.78% decline in operating profit to Rs 218.90 crore. Raw material cost as a % of total sales (net of stock adjustments) increased from 18.46% to 23.62%. Purchase of finished goods cost fell from 26.74% to 6.71%. Employee cost increased from 11.65% to 15.18%. Other expenses rose from 13.98% to 18.52%. Other income fell 74.81% to Rs 6.5 crore. PBIDT fell 11.85% to Rs 225.4 crore. Provision for interest remained nil.
PBDT fell 11.86% to Rs 225.1 crore. Provision for depreciation rose 3.09% to Rs 10 crore.
Profit before tax down 12.45% to Rs 215.10 crore. Provision for tax was expe...
Pleaselogin & subscribe to view the full report.
More Reports
|
|